Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An aggressive rhabdomyosarcoma occurring in adults. The neoplasm is characterized by the presence of bizarre round, spindle, and polygonal cells. Clinical presentation includes a rapidly enlarging painful mass usually in the lower extremities.
Biomarker and diagnostic research for adult pleomorphic rhabdomyosarcoma has been reported in the published literature.
5 clinical trials registered, 3 recruiting. Interventions under study include procedural interventions, other interventions, biologic therapy, and drug therapy. Pipeline includes 3 PHASE2, 1 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07169344](https://clinicaltrials.gov/study/NCT07169344) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:52 AM UTC
Common questions about adult pleomorphic rhabdomyosarcoma
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma |
PHASE2 |
Oslo University Hospital |
RECRUITING |
[NCT06277154](https://clinicaltrials.gov/study/NCT06277154) | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | PHASE2 | HRYZ Biotech Co. | RECRUITING |
[NCT07173972](https://clinicaltrials.gov/study/NCT07173972) | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. | PHASE2 | Oslo University Hospital | RECRUITING |
[NCT04420975](https://clinicaltrials.gov/study/NCT04420975) | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | PHASE1 | Jonsson Comprehensive Cancer Center | ACTIVE_NOT_RECRUITING |
[NCT06526897](https://clinicaltrials.gov/study/NCT06526897) | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | NA | ECOG-ACRIN Cancer Research Group | NOT_YET_RECRUITING |
52 publications have been identified in PubMed for adult pleomorphic rhabdomyosarcoma. Research spans Case Report / Case Series (52%), Review / Meta-Analysis (13%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 27 | 52% |
Research summaries | 7 | 13% |
Laboratory research | 7 | 13% |
Disease patterns and progression | 5 | 10% |
Testing and diagnosis research | 3 | 6% |
Clinical study results | 3 | 6% |
Yeung MCF (2026). [PMID: 42192570](https://pubmed.ncbi.nlm.nih.gov/42192570/). *Genes Chromosomes Cancer*. [Basic Science / Preclinical]
Zou YS (2026). [PMID: 41395670](https://pubmed.ncbi.nlm.nih.gov/41395670/). *Histopathology*. [Basic Science / Preclinical]
Giani C (2026). [PMID: 41564817](https://pubmed.ncbi.nlm.nih.gov/41564817/). *ESMO Open*. [Clinical Trial Publication]
Chen M (2026). [PMID: 41334782](https://pubmed.ncbi.nlm.nih.gov/41334782/). *Int J Surg Pathol*. [Review / Meta-Analysis]
Margotte L (2026). [PMID: 41666515](https://pubmed.ncbi.nlm.nih.gov/41666515/). *Eur J Surg Oncol*. [Epidemiology / Natural History]
Ulici V (2026). [PMID: 41780801](https://pubmed.ncbi.nlm.nih.gov/41780801/). *Mod Pathol*. [Basic Science / Preclinical]
Trecourt A (2026). [PMID: 41255082](https://pubmed.ncbi.nlm.nih.gov/41255082/). *Am J Surg Pathol*. [Basic Science / Preclinical]
Ma JQ (2026). [PMID: 41607761](https://pubmed.ncbi.nlm.nih.gov/41607761/). *World J Gastrointest Oncol*. [Case Report / Case Series]
Baldi GG (2026). [PMID: 41819027](https://pubmed.ncbi.nlm.nih.gov/41819027/). *Eur J Cancer*. [Clinical Trial Publication]
Gunasekaran K (2026). [PMID: 41728531](https://pubmed.ncbi.nlm.nih.gov/41728531/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning adult pleomorphic rhabdomyosarcoma
Updated Jun 12, 2026
A study of 39 mismatch repair-deficient sarcomas reveals recurrent histologic patterns, advocating for universal screening of pleomorphic rhabdomyosarcoma, uterine leiomyosarcoma, and undifferentiated and unclassified sarcomas. This research could influence future diagnostic and treatment strategies.
A retrospective study from the PUSH consortium evaluates outcomes in patients with advanced pleomorphic rhabdomyosarcoma treated with systemic agents. The findings contribute to understanding treatment efficacy in this ultra-rare sarcoma subtype.